Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
$0.46
$0.43
$0.19
$1.24
$16.71M1.85661,416 shs351,642 shs
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
$0.60
$0.67
$0.46
$3.07
$15.91MN/AN/A3,009 shs
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
$3.69
+4.2%
$4.00
$0.92
$16.95
$70.27M0.481.52 million shs421,053 shs
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
$0.59
+1.7%
$0.61
$0.45
$3.47
$16.92M1.9729,607 shs165,340 shs
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
0.00%0.00%0.00%0.00%0.00%
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
0.00%0.00%0.00%0.00%-3.23%
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
+4.24%+4.24%-27.50%-8.66%+84.50%
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
+1.27%+2.79%-21.57%-14.37%-79.93%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
N/AN/AN/AN/AN/AN/AN/AN/A
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
0.9059 of 5 stars
0.03.00.03.92.50.80.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
N/AN/AN/AN/A
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
N/AN/AN/AN/A
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
N/AN/AN/AN/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
$48.34M0.35N/AN/A$0.48 per share0.95
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
$110K144.65N/AN/A$0.20 per share3.00
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
N/AN/AN/AN/A$1.78 per shareN/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
$8.68M1.95N/AN/A$0.32 per share1.84

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
-$23.29M-$1.20N/AN/A-47.03%-113.57%-38.22%N/A
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
-$9.14MN/A0.00N/AN/AN/AN/AN/A
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
-$36.41MN/A0.00N/AN/A-91.03%-72.44%N/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
-$92.84M-$11.68N/AN/AN/A-1,069.29%-234.77%-47.11%5/20/2024 (Estimated)

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
N/AN/AN/AN/AN/A
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
N/AN/AN/AN/AN/A
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
N/AN/AN/AN/AN/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
N/A
1.23
1.04
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
N/AN/AN/A
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
N/A
6.39
6.39
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
N/A
0.48
0.37

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
8.65%
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
N/A
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
N/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
12.26%

Insider Ownership

CompanyInsider Ownership
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
3.30%
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
0.94%
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
N/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
10.35%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
33736.73 million35.51 millionNot Optionable
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
9526.52 million26.28 millionNot Optionable
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
1219.04 millionN/ANot Optionable
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
13128.68 million25.71 millionOptionable

MLND, CYAD, CEMI, and VBIV Headlines

SourceHeadline
StockNews.com Initiates Coverage on VBI Vaccines (NASDAQ:VBIV)StockNews.com Initiates Coverage on VBI Vaccines (NASDAQ:VBIV)
americanbankingnews.com - May 4 at 2:40 AM
VBI Vaccines Inc. (NASDAQ:VBIV) Sees Significant Growth in Short InterestVBI Vaccines Inc. (NASDAQ:VBIV) Sees Significant Growth in Short Interest
americanbankingnews.com - April 28 at 5:24 AM
VBI Vaccines (NASDAQ:VBIV) Shares Pass Below 200-Day Moving Average of $0.61VBI Vaccines (NASDAQ:VBIV) Shares Pass Below 200-Day Moving Average of $0.61
americanbankingnews.com - April 26 at 4:04 AM
VBI Vaccines (NASDAQ:VBIV) Receives New Coverage from Analysts at StockNews.comVBI Vaccines (NASDAQ:VBIV) Receives New Coverage from Analysts at StockNews.com
americanbankingnews.com - April 26 at 2:24 AM
VBI Vaccines Reports Full Year 2023 Financial ResultsVBI Vaccines Reports Full Year 2023 Financial Results
businesswire.com - April 16 at 8:00 AM
VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesVBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
businesswire.com - April 11 at 4:05 PM
VBI Vaccines secures $2 million in direct offeringVBI Vaccines secures $2 million in direct offering
investing.com - April 11 at 3:23 PM
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesVBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
businesswire.com - April 9 at 2:45 PM
VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent GlioblastomaVBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
businesswire.com - April 3 at 8:00 AM
VBI Vaccines expands collaboration with Canadian governmentVBI Vaccines expands collaboration with Canadian government
msn.com - April 2 at 5:12 PM
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine PlatformVBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
businesswire.com - April 2 at 8:00 AM
VBI Vaccines Inc. (VBIV)VBI Vaccines Inc. (VBIV)
finance.yahoo.com - March 31 at 8:25 AM
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial ResultsBrii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
finance.yahoo.com - March 22 at 7:40 AM
North Carolina biotech inks $30M deal to expand its global pipelineNorth Carolina biotech inks $30M deal to expand its global pipeline
bizjournals.com - February 15 at 3:37 PM
VBI signs deal to sell manufacturing capabilities, certain assets with Brii BiosciencesVBI signs deal to sell manufacturing capabilities, certain assets with Brii Biosciences
msn.com - February 14 at 6:34 PM
Brii Biosciences enters into multiple beneficial deals with VBI VaccinesBrii Biosciences enters into multiple beneficial deals with VBI Vaccines
thepharmaletter.com - February 14 at 1:33 PM
Strategic Licensing Agreements: Brii Bio’s Expansion into Chronic Disease Treatments with VBI VaccinesStrategic Licensing Agreements: Brii Bio’s Expansion into Chronic Disease Treatments with VBI Vaccines
finance.yahoo.com - February 14 at 1:33 PM
Why Robinhood Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving PremarketWhy Robinhood Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
benzinga.com - February 14 at 8:33 AM
VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii BiosciencesVBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences
finance.yahoo.com - February 14 at 8:33 AM
VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii BiosciencesVBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences
businesswire.com - February 14 at 7:00 AM
Brii Biosciences To Buy VBIs IP Rights In BRII-179Brii Biosciences To Buy VBI's IP Rights In BRII-179
markets.businessinsider.com - February 13 at 10:32 PM
Brii Biosciences Announces Agreement to Acquire VBIs IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial SuppliesBrii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies
prnewswire.com - February 13 at 7:04 PM
VBI Vaccines Secures Forbearance Agreement ExtensionsVBI Vaccines Secures Forbearance Agreement Extensions
msn.com - February 7 at 9:52 AM
VBI Vaccines Inc. [VBIV] Investment Guide: What You Need to KnowVBI Vaccines Inc. [VBIV] Investment Guide: What You Need to Know
knoxdaily.com - January 2 at 4:56 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Chembio Diagnostics logo

Chembio Diagnostics

NASDAQ:CEMI
Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Medford, NY.
Celyad Oncology logo

Celyad Oncology

NASDAQ:CYAD
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.
Millendo Therapeutics logo

Millendo Therapeutics

NASDAQ:MLND
As of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.
VBI Vaccines logo

VBI Vaccines

NASDAQ:VBIV
VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.